Researchers develop test to help patients with early breast treatment
with a pre-malignant breast cancer diagnosis from a biopsy, there
are three options: observation, chemoprevention or surgery, all of
which require a patient to make decisions while operating from a
place of fear and unknown outcomes. Some patients, for example,
with early breast cancer indications, might choose to have
mastectomies, rather than live in uncertainty, when the disease
state may not have progressed.
is why researchers at the University of Cincinnati (UC) are
investigating a molecular diagnostic test to determine whether,
after biopsy, someone is at high or low risk for actually
developing malignant breast cancer.
"The test aids in the
decision whether to treat aggressively or wait,” says cancer
researcher and principal investigator Georg Weber, MD, PhD, a
professor at UC’s James L. Winkle College of Pharmacy.
study, "Osteopontin and Premalignant Breast Lesions,” appears
in the Oct. 24, 2018 issue of
The British Journal of
the study, Weber, co-author Elyse Lower, MD, professor of medicine
at the UC College of Medicine, director of the UC Cancer
Institute’s Breast Cancer Center and UC Health oncologist,
and colleagues at Wroclaw Medical University in Poland, analyzed
variants of the biomarker Osteopontin (OPN) in 434 women with
premalignant breast lesions.
the sample, they determined that the presence of Osteopontin
variants can very reliably assess the risk group a patient belongs
to, thus aiding in the decision on how to proceed. "The value lies
in being able to examine invasive potential,” says Weber,
adding that prognostic biomarkers inform on the probable disease
course while predictive biomarkers provide upfront information
regarding how likely a patient is to benefit from a specific
treatment, and hence may guide the choice of available
attended medical school in Würzburg, Germany. He worked at the
Dana-Farber Cancer Institute, Harvard Medical School from 1990
through 2000. He has published over 100 scientific reports,
including many in the most respected professional journals, plus
various monographs, including textbooks on molecular oncology and
anti-cancer drugs. He holds eight patents and has additional
applications pending. His research has made key contributions to
understanding the molecular mechanisms of metastasis.
research was funded by the Marlene Harris-Ride Cincinnati/Pilot
Program. Biostatical support was provided by the University of
Cincinnati Center for Clinical and Translational Science and
Training (CCTST) with funding from the National Center for
Advancing Translational Sciences of the National Institutes of
Health (Award # 5UL1TR))1425-03).
Back to News